Skip to main content

Table 1 Assumption used to develop the base case analysis

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Assumption References
The target population is represented by patients with severe haemophilia A Product indication
The use of rFVIIIFc is considered only for prophylaxis treatment Product indication
Product consumption related to the use of drugs for surgery is not included in the analysis because no difference between the two scenario are hypothesized Assumption based on the opinion of clinical experts
Patients with inhibitors are excluded from the analysis because deserving particular treatment different from those analysed in the present analysis Product indication
Paediatric patients are exposed only to prophylaxis regimen, no on-demand treatment is considered for these patient according to current clinical practice in Italy Assumption based on the opinion of clinical experts
According to current clinical practice in Italy, paediatric patients are not exposed to treatment with plasma derived products Assumption based on the opinion of clinical experts
Age cut-off to differentiate treatment for paediatric and adults patients is considered equal to 12 years old Assumption based on the opinion of clinical experts, [7]
An equal treatment schedule is considered for both plasma derived and conventional recombinant products Assumption based on the opinion of clinical experts
The incidence of spontaneous bleeding is equal between patients treated with plasma derived and conventional recombinant products Assumption based on the opinion of clinical experts
The consumption of products for the management of spontaneous bleeding is equal between patients treated with plasma derived and conventional recombinant products Assumption based on the opinion of clinical experts
For all products compliance with prophylaxis treatment is considered to be 100% Assumption based on the opinion of clinical experts
Percentage of patients switching to rFVIIIFc is considered to do not differ among the diverse products Assumption based on the opinion of clinical experts
\